Bioorganic & Medicinal Chemistry Letters
Synthesis of oolongtheanins and their inhibitory activity on micellar
cholesterol solubility in vitro
⇑
Kazuki Ogawa, Sayumi Hirose, Hitomi Yamamoto, Masaya Shimada, Satoshi Nagaoka, Emiko Yanase
Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan
a r t i c l e i n f o
a b s t r a c t
Article history:
The synthesis of oolongtheanins (1a–d) was accomplished from EGC and/or EGCg in three steps. Oolong-
theanin-30-O-gallate (1b) showed more potent inhibitory activity on micellar cholesterol solubility than
did EGCg.
Received 11 November 2014
Revised 25 December 2014
Accepted 5 January 2015
Available online 9 January 2015
Ó 2015 Elsevier Ltd. All rights reserved.
Keywords:
Catechin
Oolongtheanins
Micelle
Cholesterol
Tea (Camellia sinensis) is a globally popular beverage. It is clas-
sified as green tea, oolong tea and black tea according to the fer-
mentation conditions of the tea leaves. Oolong tea has attracted
attention because of its health benefits, such as its anti-obesity
effects.1 Obesity and hyperlipidemia increases the risk of various
diseases, such as heart disease and cerebral arterial disease.2
Oolong tea is traditionally reported to be effective for the preven-
tion of obesity and improvement of lipid metabolism. Recently,
anti-hypocholesterolemic activity has been reported in the green
tea catechins and the polymerized polyphenols of black tea and
oolong tea.3–9 Oolongtheanins (1a–1d; Fig. 1)10 are one of the char-
acteristic polyphenols found in oolong tea and are also predicted to
exert various bioactive effects.11,12 Recently their chemical struc-
tures were revised by Tanaka et al.2 However, detailed studies on
their activity have thus far been limited because the numerous
components found in the extract leads to a complicated mixture
and thus, preparative scale isolation is difficult. A few synthetic
studies towards 1a and 1b have been reported using enzymatic
oxidation.13 The generation of oolongtheanin-30-O-gallate (1b)
was reported as a byproduct during the synthesis of theasinensin
A (2) using CuCl2 as an oxidizing agent.14,15 However, an efficient
synthetic method for oolongtheanins (1a–d) has not been reported.
In a previous study, we proved the mechanism for the formation of
1a and 1b from EGC (3) or EGCg (4).16 In this study, we investigated
effective synthetic methods towards 1a and 1b, which are
homodimers of 3 and 4, and the syntheses of 1c and 1d, which
are heterodimers of 3 and 4.
We also examined the ability of synthetic oolongtheanins to
decrease the micellar solubility of cholesterol using a model
micelle system in vitro.17
First, the synthesis of 1a and 1b, which are homodimers of 3
and 4, was investigated (Scheme 1). Previously, we achieved the
transformation of 4 to 1b in three steps via two intermediates.
Therefore, we now moved on to optimizing each step of the
reaction to inhibit formation of byproducts and to increase the
yields of oolongtheanins as follows: for the first step, a solution
of 4 was treated with CuCl2ꢀ2H2O in 30% aq MeOH under optimal
conditions. The reaction was monitored by HPLC and three new
peaks were observed (data not shown). The chemical structures
corresponding to these peaks were determined by LC/MS and
NMR to be 2, 5b, and the MeOH adduct of 5 (5MeOH), respectively.
The transformation of 5MeOH to 5b was not observed. Hence, the
same reaction was carried out in 30% aq 1,4-dioxane, which would
not form an adduct, and the yield of 5b was improved. The result-
ing solution was subjected to HP20SS column chromatography,
and was eluted with CH3CN after washing with water to remove
CuCl2ꢀ2H2O, providing crude product 5b, which was used directly
in the next reaction. The transformation of 3 to 5a was performed
in the same manner.
Abbreviations: EC, (ꢁ)-epicatechin; EGC, (ꢁ)-epigallocatechin; ECg, (ꢁ)-epicat-
echin-3-O-gallate; EGCg, (ꢁ)-epigallocatechin-3-O-gallate.
Crude 5b was transformed to 6b by a dehydration and rear-
rangement reaction. The reaction was performed under anhydrous
⇑
Corresponding author. Tel./fax: +81 08 58 293 2914.
0960-894X/Ó 2015 Elsevier Ltd. All rights reserved.